HYPE3.SA- Hypera S.A.
🇧🇷 BRLHealthcare · Drug Manufacturers - Specialty & Generic
Price & Performance
Performance
Analysis & Verdict
Analyst Ratings
Strong BuyWall Street consensus from 15 analysts
12-Month Price Target
$29.83
Based on analyst estimates; price targets are opinions, not guarantees.
Fair Value Estimates
Current price: $25.16
Graham Number
√(22.5 × EPS × Book Value)
$34.89
Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.
Bazin Ceiling Price
Avg. Annual DPS (5Y) ÷ 6%
$19.91
Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.
These are simplified estimates. Not financial advice.
Buy & Hold Checklist
Quality criteria for long-term holding
9/10
90% score
Pays dividends
13Y hist.13+ years of dividend history
Dividend consistency (5Y+)
13 yrsUninterrupted dividend payments for at least 5 years
ROE above 10%
13.2%Return on equity - measures how efficiently capital is used
Positive profit margin
19.8%Net profit margin must be positive - company earns more than it spends
Revenue growth (annual)
+8.5%Annual revenue must be growing compared to the prior year
Earnings growth (annual)
+4.5%Annual earnings must be growing compared to the prior year
Debt/Equity below 2×
53.28×Low financial leverage reduces risk of distress
Current ratio above 1
1.86×Short-term assets must cover short-term liabilities
Daily liquidity above $5M
$78M/dayHigh trading volume ensures easy entry and exit
Dividend yield above 0%
4.18%Stock must distribute income to shareholders
Financials
Revenue & Results
Key Statistics
Earnings
Next Earnings
Oct 27, 2026
24
days
EPS (TTM)
$2.64
P/E (TTM)
9.5
Fwd P/E
7.9
Dividends & Income
Dividends
Current DY
4.18%
5Y Avg Annual
$1.1083
Last Payment
$0.2630
Ex-Date
09/29/2026
Annual dividends paid per share
| Ex-Date | Payment | Amount | Est. DY |
|---|---|---|---|
Latest09/29/2026 | 10/13/2026 | $0.2630 | 4.18% |
06/29/2026 | 07/13/2026 | $0.2630 | 4.18% |
04/01/2026 | 04/15/2026 | $0.2630 | 4.18% |
12/29/2025 | 01/12/2026 | $0.2895 | 4.60% |
09/29/2025 | 10/13/2025 | $0.2895 | 4.60% |
06/27/2025 | 07/11/2025 | $0.2895 | 4.60% |
03/28/2025 | 04/11/2025 | $0.2895 | 4.60% |
12/30/2024 | 01/13/2025 | $0.2878 | 4.58% |
Magic Number
Shares needed to self-fund your next purchase
$25.16
Price
$0.2630
Last div. (quarterly)
96
shares
Own 96 HYPE3.SA shares ($2,415.36) and each quarterly dividend pays for 1 new share - the snowball runs on its own.
Investment target
$2,415.36
New shares / year
+4 shares
Dividend Calculator
4.17% yieldEstimate HYPE3.SA dividend income at the current rate.
Per year
$417.33
Per month
$34.78
≈ 397.5 shares at $1.05/share a year. Estimate only - dividends can be cut or raised.
Tools & Simulators
HYPE3.SA vs Peers, Indexes & Commodities
?Click a card below to plot it on the chart
Loading history…
Parameters
Final value
R$ 552.068,46
Total invested
R$ 130.000,00
Total interest
R$ 422.068,46
Balance over time
Period breakdown
| Period | Balance | Invested | Interest |
|---|---|---|---|
| Start | R$ 10.000,00 | R$ 10.000,00 | R$ 0,00 |
| Year 1 | R$ 17.523,25 | R$ 16.000,00 | R$ 1.523,25 |
| Year 2 | R$ 25.949,29 | R$ 22.000,00 | R$ 3.949,29 |
| Year 3 | R$ 35.386,45 | R$ 28.000,00 | R$ 7.386,45 |
| Year 4 | R$ 45.956,07 | R$ 34.000,00 | R$ 11.956,07 |
| Year 5 | R$ 57.794,05 | R$ 40.000,00 | R$ 17.794,05 |
| Year 6 | R$ 71.052,59 | R$ 46.000,00 | R$ 25.052,59 |
| Year 7 | R$ 85.902,15 | R$ 52.000,00 | R$ 33.902,15 |
| Year 8 | R$ 102.533,65 | R$ 58.000,00 | R$ 44.533,65 |
| Year 9 | R$ 121.160,94 | R$ 64.000,00 | R$ 57.160,94 |
| Year 10 | R$ 142.023,50 | R$ 70.000,00 | R$ 72.023,50 |
| Year 11 | R$ 165.389,57 | R$ 76.000,00 | R$ 89.389,57 |
| Year 12 | R$ 191.559,57 | R$ 82.000,00 | R$ 109.559,57 |
| Year 13 | R$ 220.869,97 | R$ 88.000,00 | R$ 132.869,97 |
| Year 14 | R$ 253.697,61 | R$ 94.000,00 | R$ 159.697,61 |
| Year 15 | R$ 290.464,57 | R$ 100.000,00 | R$ 190.464,57 |
| Year 16 | R$ 331.643,57 | R$ 106.000,00 | R$ 225.643,57 |
| Year 17 | R$ 377.764,05 | R$ 112.000,00 | R$ 265.764,05 |
| Year 18 | R$ 429.418,98 | R$ 118.000,00 | R$ 311.418,98 |
| Year 19 | R$ 487.272,51 | R$ 124.000,00 | R$ 363.272,51 |
| Year 20 | R$ 552.068,46 | R$ 130.000,00 | R$ 422.068,46 |
What is compound interest?
Compound interest means that the interest you earn in one period is added to your principal, so in the next period you earn interest on a larger base. This creates exponential growth: the longer your time horizon, the more dramatic the effect.
Which rate should I use?
The Ibovespa, Brazil's main stock index, has historically returned roughly 12%/year in nominal terms over long periods. The CDI, the interbank interest benchmark, sits around 11% and tracks the Selic rate. The poupança (savings) pays about 6%, while inflation (IPCA) has run near 5%. Nominal Brazilian returns look high next to US figures mainly because inflation is higher, so compare real (inflation-adjusted) returns when planning.
Formula used
FV = PV × (1+r)^n + PMT × ((1+r)^n − 1) / rwhere r is the monthly rate, n is the number of months, PV is the initial investment, and PMT is the monthly contribution. Annual rates are converted to monthly viar = (1 + annual%)^(1/12) − 1.
For educational purposes only. Not financial advice. Past returns do not guarantee future results.
Get the weekly market breakdown
Real numbers, plain English, no hype. The stories and data that actually move stocks and crypto, straight to your inbox.
Subscribe freeDiscussion
Sign in to join the discussionSign inLoading…
Discover
Related Assets
Healthcare
Related Articles
About Hypera S.A.
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptics products under Merthiolate brand; Herbal medicine products under Maracugina, Eparema, Tamarine, and Naturetti brands; gastrointestinal products under Dramin, Estomazil, Engov, Lacto-purga, gastrol, Epocler, Bifilax, and Pepsamar brands. In addition, the company provides generics products under neo quimica brand; skicare products under episol, epidrat, simple organic, and bioage brands; supplements and vitamins products Addera, Biotonico Fontoura, Colflex, and Vitasay brands; and other products under Nebacetin, Cepacol, ESCABIN, Mirrorelax, Ammy, Nesina, and Diprospan brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Location
São Paulo, Brazil
Employees
10,564
CEO
Mr. Breno Toledo Pires de Oliveira
Stock Market ROI Pro
All features, zero ads- web & app
Unlock every feature, ad-free, across our website and iOS app.
Hypera S.A. (HYPE3.SA) stock trades at $25.16, up 1.90% on the day. With a market capitalization of $17.71 billion, HYPE3.SA is a large-cap healthcare stock. It trades at a price-to-earnings (P/E) ratio of 9.5, a forward P/E of 7.9 and earnings per share (EPS) of $2.64. Over the most recent period the company reported 9% year-over-year revenue growth and a net profit margin of 19.8%. Below you'll find HYPE3.SA's full fundamentals, fair-value estimates, dividend history, earnings and our buy, hold or avoid verdict for 2026.
HYPE3.SA - Frequently Asked Questions
Is Hypera S.A. (HYPE3.SA) a good stock to buy in 2026?
Hypera S.A. (HYPE3.SA) shows strengths such as a strong 20% net margin, while risks include high leverage (debt/equity of 53.3). Whether HYPE3.SA is a good buy in 2026 depends on your time horizon and risk tolerance - review the full bull case, bear case and fair-value estimates above. This is informational analysis, not financial advice.
What is HYPE3.SA's stock price today?
Hypera S.A. (HYPE3.SA) trades at $25.16 as of October 2, 2026, up 1.90% on the session. Prices on this page update throughout the trading day.
Does HYPE3.SA pay a dividend?
Yes. Hypera S.A. pays an annual dividend of $1.05 per share, a dividend yield of 4.18%. The most recent ex-dividend date was September 29, 2026. Its payout ratio is about 42% of earnings.
Is HYPE3.SA overvalued?
With a P/E ratio of 9.5×, HYPE3.SA trades at a relatively modest valuation for the healthcare sector. Its PEG ratio is 0.76 (below 1, which can signal growth at a reasonable price). See the Fair Value Estimates section above for Graham Number and dividend-based price targets.
What is HYPE3.SA's market cap?
Hypera S.A. (HYPE3.SA) has a market capitalization of $17.71 billion, classifying it as a large-cap stock in the Healthcare sector.
Disclaimer: This page - including any buy/hold/avoid view, fair value or price estimate - is generated from market data for informational and educational purposes only and does not constitute financial, investment or trading advice. Data may be delayed or inaccurate. Always do your own research and consult a licensed financial advisor before making any investment decision.